TRELSTAR - Treatment Regimen

Treatment Regimen

How Long You Will Take TRELSTAR?
Because TRELSTAR does not cure prostate cancer, your doctor will probably want you to keep taking it as long as it keeps working. Your doctor may be able to tell if it is working by doing laboratory tests such as testing your blood level of prostate-specific antigen (PSA) or testosterone. Your doctor may also want to order imaging studies such as a bone scan while you’re taking TRELSTAR.

What Should You Do If You Miss An Injection?
In order to get the full benefit of taking TRELSTAR, you should be sure to get your injection on time when it is due. If you are going to be away from home and have to miss an injection, check with your doctor. If you miss an injection, contact your doctor as soon as you can.

Staying on Top of Your Treatment.
As with any cancer treatment, it is important that you get your TRELSTAR shots regularly. TRELSTAR.com has developed a Treatment Diary that will help you stay on top of your treatment.

There are also a number of support groups and additional resources available that will help inform you so that you can work with your doctor in choosing treatment and lifestyle that is right for you.

Learn more.
To learn more, download the Trelstar Patient Education Brochure.

TRELSTAR FAQs

Indications and Usage
TRELSTAR^® Depot and TRELSTAR^® LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.

Safety Information

The most commonly reported adverse events associated with the use of TRELSTAR^® Depot/TRELSTAR^® LA included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock and angioedema have been received since 1986 (global experience) . As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, spinal cord compression, or urethral or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed.